-37.8%
NFLX vs MRNA
+511.3%
-549.1%
-46.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | -2.2% | -3.1% | -5.3% |
| 7D | -4.2% | +5.5% | -9.7% | -4.4% |
| 30D | +5.5% | +158.7% | -153.3% | +1.5% |
| 3M | -4.1% | +182.1% | -186.2% | -7.0% |
| 6M | -20.7% | +151.8% | -172.5% | -23.1% |
| YTD | -16.5% | +393.6% | -410.1% | -18.3% |
| 1Y | -37.8% | +499.5% | -537.2% | -38.2% |
| All | -37.8% | +511.3% | -549.1% | -38.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling